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Abstract
Background—Drugs that exhibit close margins between therapeutic and toxic blood 
concentrations are considered to have a narrow therapeutic index (NTI). The Food and Drug 
Administration has proposed that NTI drugs should have more stringent bioequivalence standards 
for approval of generic formulations. However, many immunosuppressant drugs do not have a 
well-defined therapeutic index (TI).
Methods—We sought to determine whether safety, efficacy, and pharmacokinetic data obtained 
from the medical literature through a comprehensive literature search could be used to estimate the 
TI of cyclosporine, tacrolimus, and sirolimus. In this analysis, we considered TI ≤2 as a criterion 
to define a drug as having an NTI.
Results—Published literature indicates that cyclosporine has a TI of 2–3, which falls just short of 
our criteria to be classified as having an NTI. We found sirolimus and tacrolimus to have a 
therapeutic range of 5–12 ng/mL and of 5–20 ng/mL, respectively, but were unable to calculate the 
TI.
Conclusion—Although current literature does not provide a clear indication that these drugs 
have an NTI, the routine use of therapeutic drug monitoring in clinical practice suggests that more 
stringent testing of their pharmacokinetic and pharmacodynamic properties should be performed 
prior to the approval of generic formulations.
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Immunosuppression is an important aspect of successful organ transplantation. 
Cyclosporine, tacrolimus, and sirolimus are drugs that are commonly used for 
immunosuppression in transplant patients to prevent graft rejection.1 However, the benefits 
of preventing rejection must be carefully balanced with the risks of drug toxicities, including 
increased risk of infections and malignancies.2,3 Immunosuppressive drugs are often 
considered to have a narrow therapeutic index (NTI), exhibiting a very close margin between 
therapeutic and toxic blood concentrations.4 Small changes in the dose of an NTI drug can 
lead to changes in exposure that are associated with therapeutic failures if the therapeutic 
range is not reached, or unwanted side effects if the therapeutic range is exceeded.
In order for a new generic version of a drug to receive approval from the Food and Drug 
Administration (FDA), the manufacturer must demonstrate that the generic formulation is 
pharmaceutically equivalent and bioequivalent to the innovator formulation.5 The current 
FDA bioequivalence criteria require that the 90% confidence interval (CI) of the ratio 
between the geometric mean of a generic product and the reference product fall within 80–
125%.6 In 2010, the FDA proposed that drugs classified as NTI should have more stringent 
regulatory standards for the approval of generic formulations. The proposed new 
bioequivalence criteria require reference-scaled bioequivalence testing and a variability 
comparison test for generic drugs with an NTI.7
In order for these new standards to be implemented, it is necessary to define which drugs 
should be classified as NTI. NTI drugs generally have the following characteristics: (a) there 
is little separation between therapeutic and toxic doses (or the associated blood/plasma 
concentrations), (b) sub-therapeutic concentrations may lead to serious therapeutic failure, 
(c) they are subject to therapeutic monitoring based on pharmacokinetic (PK) or 
pharmacodynamic (PD) measures, (d) they possess low-to-moderate (i.e., no more than 
30%) within-subject variability, and (e) doses are often adjusted in very small increments 
(less than 20%) in clinical practice.8 NTI classification requires the estimation of therapeutic 
index (TI), which is not well established for many available immunosuppressants. Pollard et 
al. reported that conversion from innovator formulations to generic formulations of 
immunosuppressants has been associated with increased renal graft failure and biopsy-
proven acute rejection (BPAR), which has led to a lack of confidence by providers in 
prescribing generic products.9 If certain immunosuppressants were to be identified as NTI 
drugs, application of the new criteria would be expected to improve patient safety, enhance 
physician confidence in generic products, and decrease health care costs due to increased 
generic drug prescription. The purpose of our study was to determine whether the medical 
literature can be used to determine the TI of immunosuppressants commonly used to prevent 
rejection in renal transplant patients. We focused our assessment on renal transplantation, as 
this is the most common type of organ transplantation, which has the largest body of 
literature regarding the use of immunosuppressant therapies.
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Through collaboration with the FDA and review of international regulatory agency 
documents, we focused on three immunosuppressants as candidate NTI drugs that may 
benefit from tighter bioequivalence standards for generic drug development: cyclosporine, 
tacrolimus, and sirolimus.
Literature search
We performed a literature search with no time restriction to identify all studies reporting PK, 
safety, and efficacy data for these immunosuppressant drugs when used following the renal 
transplantation in adults using PubMed and Embase with the aid of professional librarians 
from Duke University Medical Library (Table 1).
A study team member initially reviewed all identified article abstracts and selected those for 
full text review that compared the efficacy or safety of the drug of interest to a comparator or 
contained therapeutic drug monitoring (TDM) information. Full text articles meeting the 
study criteria and containing sufficient safety, efficacy, pharmacokinetics or TDM data were 
included. When it was uncertain whether an article should be included and data extracted 
into the study database, the manuscript was reviewed by a second study team member to 
reach consensus. As a quality assurance measure, 5% of the extracted data underwent an 
independent full review by a third study member.
For each immunosuppressant, we extracted efficacy and safety data from all prospective 
randomized controlled trials, and we extracted PK data from all identified PK studies into a 
study-specific drug database. Specific variables extracted included study demographics, drug 
dosing and formulation, PK parameters (e.g., Cmax, area under the concentration versus 
time curve (AUC), clearance), and efficacy data (study phase, primary outcome, study 
result). Safety data collected included warning and precautions listed in the drug label as 
well as all adverse events (AEs) with a placebo adjusted frequency >10%.
Therapeutic index estimation
For each immunosuppressant drug, we reported the type and incidence of AE and the range 
of drug dosing and blood concentrations for which toxicity was described, the type and 
frequency of primary outcomes in efficacy studies, the blood drug concentration for which 
efficacy was described, and, when available, the effective versus toxic concentration and 
dose (therapeutic range). The efficacy of both cyclosporine and tacrolimus with mono- or 
combination therapy was most commonly assessed using three measures: (1) BPAR, (2) 
graft failure, and (3) patient death. Sirolimus efficacy with mono- or combination therapy 
was assessed using three similar measures: (1) BPAR; (2) patient death; and (3) a composite 
end point of death, graft loss, or BPAR. We extracted the minimum toxic concentration and 
the minimum effective concentration of the study population in the literature report and 
defined the TI as the ratio between the minimum toxic concentration to the minimum 
effective concentration. Even though FDA does not specify a threshold value to determine 
whether a TI is narrow, in this analysis, we considered a TI ≤2 as one criterion to support the 
classification as an NTI drug.
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Cyclosporine is a calcineurin inhibitor that has been used as an immunosuppressant for the 
prevention of rejection in renal transplant patients since the early 1980s.10 Our literature 
search for cyclosporine yielded 373 articles with 122 articles containing data sufficient for 
extraction (Table 2).
Safety—AEs associated with cyclosporine use in patients with renal transplant varied and 
involved many organ systems (Table 3).11–20 Common AEs were hyperlipidemia; 
comparator-adjusted frequency, 21%21; hypertension, 26%22; cardiac events, 19%23; 
gingival hyperplasia, 13–43%24,25; and increased creatinine, 12%.26 The incidence of AEs 
was not consistently shown to be dose related, and observed drug concentrations among 
those with certain AEs were often similar to those in patients without these events.27,28 One 
study of 118 renal transplant patients found no difference in cyclosporine PK parameters for 
patients who had nephrotoxicity (≥25% increase in serum creatinine), liver toxicity, or post-
transplant infection relative to peers without these conditions.27 Cyclosporine nephrotoxicity 
potentially threatens renal allograft survival and provides a rationale for careful dose 
titration.29–31 At least one study demonstrated that decreasing cyclosporine dose or stopping 
cyclosporine during the maintenance phase of immunosuppression led to the improved renal 
function over time compared to those who stayed on cyclosporine.32
Efficacy—Cyclosporine was typically administered as part of a multiple drug 
immunosuppressant regimen. Cyclosporine appeared to have similar efficacy to tacrolimus 
but greater efficacy than sirolimus and azathioprine.13,26,33 A randomized trial comparing 
cyclosporine and prednisone to azathioprine and prednisone in cadaveric renal transplant 
patients found that cyclosporine resulted in better graft and patient outcomes than 
azathioprine.33 Another randomized trial comparing cyclosporine and sirolimus to 
tacrolimus and sirolimus found that BPAR and graft survival were similar for the two 
regimens.34 A third trial compared a combination immunosuppressant regimen containing 
cyclosporine to one containing sirolimus and found that patients receiving cyclosporine had 
lower rates of BPAR and death than those receiving sirolimus.13 Efficacy was not entirely 
predicted by drug dose and concentration alone; rather, other PK parameters, such as AUC, 
seemed to better predict cyclosporine efficacy.35
Therapeutic range and drug monitoring—Given available evidence, we were not able 
to determine the therapeutic range of cyclosporine; it appears to differ with time after 
transplantation, concomitant medications, and individual pharmacokinetics. The ranges of 
drug exposure associated with efficacy in prior studies varied greatly in the first three 
months: trough concentrations, 120–350 ng/mL; peak [2-hour] concentrations, 700–2000 
ng/mL; and AUC at 12 hours, 3000–8000 ng · h/mL (Table 3). Target concentration ranges 
decreased over time, with some studies advocating for troughs as low as 50 ng/mL beyond 
one year post-transplant.36 Further, there appears to be notable overlap of these target values 
with those associated with AEs.
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Therapeutic index estimation—The above estimates suggest a TI of 2–3 for 
cyclosporine. Yet, TDM and individualization of therapy based on clinical presentation are 
essential.37,38 The optimal PD target, timing, and specimen type that will predict efficacy 
while minimizing the risk for toxicity has not been well defined though several studies have 
attempted to do so (Table 4). Trough concentrations are the most widely used metric for 
dose titration; however, the wide variability in absorption and PK, as well as an inconsistent 
correlation with clinical outcome, prompted search for other PD targets.39–42
Tacrolimus
Tacrolimus is a newer calcineurin inhibitor that is now more commonly used than 
cyclosporine.10 Our literature search for tacrolimus yielded 244 articles, 106 of which 
contained safety and/or efficacy data sufficient for extraction.
Safety—AEs associated with tacrolimus use in renal transplant patients were varied (Table 
2).11,18,43–49 Nephrotoxicity was the adverse effect most closely tied to tacrolimus dosing.50 
One study found that three of five cases of nephrotoxicity were associated with tacrolimus 
trough concentrations >10 ng/mL.51 The analysis of 92 cadaveric renal transplant recipients 
found a linear association between increasing tacrolimus trough blood concentrations and 
higher rates of nephrotoxicity (increase from the post-transplant serum creatinine nadir by 
≥0.5 mg/dL).52 The relationship between the frequency of infection and the concentration of 
tacrolimus was unclear. One study found that there was no difference in the proportion of 
patients developing a bacterial, viral, or fungal infection when the goal trough concentration 
was 1.5–3 ng/mL compared to a goal trough concentration of 4–7 ng/mL,53 and another 
study noted no infections in patients with trough concentrations >10 ng/mL.51 A third study 
found that the trough and peak tacrolimus concentrations were higher in patients who 
developed an infection within six weeks of their renal transplant than in patients who did not 
develop an infection.54
Efficacy—Tacrolimus was typically given with other immunosuppressant agents, which 
varied based on immunologic parameters at the time of transplant and clinician preference. 
Dosing was most commonly based on blood trough levels, with target trough concentrations 
varying widely from 1.5–40 ng/mL.48,53 Target trough concentrations were typically higher 
in the 1–3 months immediately following the transplantation. A lower target trough 
concentration was often used as the time since transplantation increased.55–58 A large 
multicenter, randomized, controlled trial in renal transplantation demonstrated that a 
tacrolimus-based immunosuppressant regimen with a low goal trough concentration of 3–7 
ng/mL resulted in a superior mean glomerular filtration rate and graft survival with a lower 
incidence of acute rejection than the comparator arms.12
Therapeutic range and drug monitoring—The dose range associated with efficacy 
and toxicity partially overlapped. Efficacy did not appear to always be concentration-related 
(Table 4).55,59–61 The toxicity of tacrolimus increased gradually with increasing blood 
concentrations in some studies,48,51,55,62 while in others, the relationship was less clear 
(Table 3).48,53,61,63 Blood concentrations in patients without toxicity often did not differ 
significantly from others who experienced adverse effects.54
Ericson et al. Page 5













Therapeutic index estimation—Based on the available medical literature, the optimal 
therapeutic range for tacrolimus is variable and the TI could not be estimated; therefore, we 
were unable to use the TI as a means of classifying tacrolimus as an NTI drug.
Sirolimus
Sirolimus is an inhibitor of the mammalian target of rapamycin and is sometimes used 
instead of or with a calcineurin inhibitor in renal transplant patients.64 Our literature search 
for sirolimus yielded 142 articles, 45 of which contained safety and/or efficacy data 
sufficient for extraction.
Safety—AEs associated with sirolimus’ use in renal transplant patients were varied (Table 
2).65–70 The prevalence of AEs associated with sirolimus was dose related in some 
studies.65,67 The incidence of AEs including malignancy, anemia, hypertension, abnormal 
kidney function, and upper respiratory infection were significantly higher in patients 
receiving the sirolimus and cyclosporine combination therapy compared with sirolimus 
monotherapy.71,72
Efficacy—Sirolimus was administered as monotherapy or in conjunction with calcineurin 
inhibitors, such as tacrolimus or mycophenolate mofetil, to provide steroid-free 
immunosuppression. The effective dose range of sirolimus varied widely (0.5–5 mg per day) 
and may have been related to co-administered immunosuppressant drugs (e.g., cyclosporine, 
tacrolimus, and steroids).
Therapeutic range and drug monitoring—The dose range associated with efficacy 
and toxicity partially overlapped with both 100% patient survival and a high incidence of 
hyperlipidemia and new onset diabetes mellitus occurring at doses of 2–4 mg/day.67,73 
Overall toxicity of sirolimus increased gradually with increasing blood concentrations. 
Blood concentrations in patients with favorable immunosuppressant outcomes did not differ 
significantly from blood concentrations in patients who experienced AEs (Tables 3 and 4). 
Data from 150 renal transplant recipients on a regimen of sirolimus, cyclosporine, and 
prednisone found an association between trough sirolimus concentrations and both AEs and 
efficacy. Sirolimus concentrations <5 ng/mL were predictive of acute rejection, whereas 
concentrations >15 ng/mL were linked with hypertriglyceridemia, thrombocytopenia, and 
leukopenia.74 For patients receiving sirolimus with a calcineurin inhibitor and a 
corticosteroid, a therapeutic range of 5–12 ng/mL has been recommended.75,76 If the 
regimen does not include a calcineurin inhibitor, a higher range (12–24 ng/mL) has been 
recommended.75,76 TDM is recommended for the use of sirolimus in all patients especially 
in those likely to have altered drug metabolism and who are at high risk for rejection.
Therapeutic index estimation—Based on the available medical literature, the optimal 
therapeutic range for sirolimus varies depending if it is co-administered with a calcineurin 
inhibitor or not. As a result, more than one TI can be derived.
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Our comprehensive literature search identified many studies evaluating the safety, efficacy, 
and PK data for these immunosuppressant drugs. The published literature indicates that 
cyclosporine has a TI of 2–3. While we found sirolimus to have a therapeutic range of 5–12 
ng/mL and tacrolimus to have a therapeutic range of 5–20 ng/mL, based on published 
studies, we were unable to estimate the TIs for sirolimus and tacrolimus.
Although studies considering a wide range of medications have demonstrated 
bioequivalence of generic medications to innovator medications, there are considerable 
concerns among physicians and patients regarding the safety and efficacy of generic 
immunomodulators.4,77–79 While much of the evidence for these concerns is anecdotal, 
retrospective database studies seemed to suggest worse outcomes for renal transplant 
patients receiving generic formulations. A single-center retrospective review found that 88 
renal transplant patients treated with a generic cyclosporine formulation were significantly 
more likely to experience BPAR than 100 patients treated with innovator cyclosporine.80 
The analysis of a large database generated as a part of the Collaborative Transplant Study 
found that the 397 patients treated with generic cyclosporine had 10% lower graft survival at 
one-year post-transplant than the 16,801 patients treated with the innovator formulation (P < 
0.01).9 However, the interpretation of these retrospective studies is challenging because there 
may be unrecorded differences between the patients that received the generic and those that 
received the innovator product. We are not aware of any studies demonstrating a difference 
in clinical outcomes for renal transplant patients receiving a generic formulation of 
tacrolimus compared to the innovator formulation. However, an average decrease of 12% in 
the concentration-to-dose ratio has been described when switching from innovator 
tacrolimus to a generic formulation while some other studies suggest similar dosing 
requirements and trough concentrations between the generic and innovator treatment 
arms.81–84 Most of these studies recommend close TDM when changing a patient from 
innovator to generic formulations, which may offset cost saving associated with the use of 
generic formulations.77,78 Studies comparing the effectiveness of generic formulations of 
sirolimus with the innovator formulation have not yet been published.
If the FDA were to enact tighter bioequivalence standards for generic formulations of certain 
drugs, this could result in decreased toxicity and sustained efficacy for patients switching 
from brand-name formulations. Clinicians and patients could then have more confidence in 
the less expensive products, likely leading to health care cost savings. Tighter 
bioequivalence standards, however, are not as necessary for drugs that have a wide TI, as 
larger variations in patient exposure can be well tolerated. Identification of NTI drugs is, 
therefore, key to the implementation of new bioequivalence standards.
In our study, we used a comprehensive literature search to assess the TI of certain 
immunosuppressants used in renal transplant patients. A TI <2 is one criterion used to 
determine whether these drugs could be classified as NTI based on available evidence. 
Health Canada, the European Medicines Agency, and FDA consider cyclosporine to be a 
NTI drug.85 We were not able to calculate the TI for tacrolimus or sirolimus. Tacrolimus has 
been considered to be an NTI drug by experts in the United States and internationally and is 
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so classified by the FDA, European Medicines Agency, and Health Canada. For all three of 
these drugs, TDM is necessary in at least some clinical situations, and there are some 
concentration-dependent effects on efficacy and toxicity. The routine use of TDM in clinical 
practice suggests a clinical consensus that a NTI may be present and that more stringent 
testing of the PK and quality control properties should be performed prior to approval of 
generic formulations. In fact, after our data collection and analysis had been completed, the 
FDA recommended that sirolimus be considered to have a NTI.86 Approval of generic 
formulations of these drugs with stringent testing of PK and quality control properties could 
reduce the potential risk of adverse effects or therapeutic failure.
An advantage of our study is the inclusion of an exhaustive systematic review of all of the 
toxicity and efficacy data available in the medical literature for these immunomodulators. 
Based on the compiled information, we were able to calculate therapeutic indices for 
cyclosporine to aid in its consideration as NTI drugs. Our study is limited by the method of 
literature review: our results are based on a wide variety of trials that included different drug 
dosages, therapeutic targets, and monitoring regimens. Thus, the results of our review may 
be strengthened when combined with other methods to support an NTI classification, 
including PK-PD modeling approaches, to determine which drugs should be subjected to 
more stringent bioequivalence criteria by regulatory agencies. Because most renal transplant 
patients receive more than one immunosuppressive medication, it is difficult to fully 
attribute efficacy or safety to the concentration of a single drug. We reported comparator-
adjusted AEs where possible in an attempt to better quantify AEs attributable to the drug of 
interest. A better source of data regarding safety and efficacy of generic formulations would 
be prospective clinical trials in which patients are randomized to continuing on brand-name 
formulations versus switching to a generic formulation. However, such trials usually require 
a large number of study subjects to draw conclusions on the difference or equivalence in 
safety or efficacy outcomes, and it is not feasible to compare all possible NTI innovator 
drugs to all possible generic formulations. Most of the studies included in our analysis did 
not describe the laboratory technique(s) used to determine the blood concentration of the 
drug of interest. Differences in techniques between studies or over time may account for a 
range of values associated with toxicity and efficacy. Finally, our estimation of the TI was 
based on the population therapeutic range, which may be wider than that of an individual. 
Therefore, we may have overestimated the TI that can be applied to an individual.
CONCLUSION
A systg/mLematic literature review approach offers a low-cost alternative method to 
estimate the TI of these drugs when sufficient data are available. However, our method 
cannot overcome significant gaps in the literature. Although current literature does not 
provide a clear indication that these drugs have an NTI, the routine use of TDM in clinical 
practice suggests that more stringent testing of their PK and pharmacodynamic properties 
should be performed prior to the approval of generic formulations to ensure bioequivalence 
in the clinical setting.
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AUC area under the curve
BPAR biopsy-proven acute rejection
CI confidence interval
Cmax maximum blood concentration
FDA Food and Drug Administration
NTI narrow therapeutic index
PD pharmacodynamics
PK pharmacokinetic
TDM therapeutic drug monitoring
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1 “pharmacokinetics” [Subheading] OR “Pharmacokinetics” [Mesh] OR “pharmacology” [Subheading] OR “Dose-Response 
Relationship, Drug” [Mesh] OR “Metabolic Clearance Rate” [Mesh] OR “Maximum Tolerated Dose” [Mesh] OR “Drug 
Monitoring” [MeSH] OR “Drug Tolerance” [Mesh] OR “Administration and dosage” [Subheading] OR “toxicity” [Subheading] 
OR “drug toxicity” [Mesh] OR “pharmacokinetics” [tiab] OR “dosing” [tiab] OR “dosage” [tiab] OR “dose” [tiab] OR 
“concentration” [tiab]
2 “Drug of choice” [Mesh] OR “Drug of choice” [tiab]
3 #1 AND #2 Limits: Adult 19+ years
4 (“Renal transplant” [tiab] OR “Renal transplantation” [tiab] OR “Kidney Transplant” [tiab] OR “Kidney Transplantation” [tiab] 
OR “Kidney Transplantation” [Mesh]) AND (reject*[tiab] OR “Graft Rejection” [Mesh])
5 #3 AND #4
6 #5 Limits: English
7 #6 NOT “case reports” [publication type]
Embase search:
1 “pharmacokinetics”/exp OR “pharmacokinetics”:ab,ti OR “pharmacodynamics”/exp OR “pharmacological parameters”/exp OR 
“dd_pk”:lnk OR “dd_pd”:lnk OR “Drug toxicity and intoxication”/exp OR “Toxicological parameters”/exp OR “Drug 
safety”/exp OR “Drug efficacy”/exp OR “dosage”:ab,ti OR “dose”:ab,ti OR “dosing”:ab,ti OR “Drug of choice”/exp OR “Drug 
of choice”:ab,ti OR “therapeutic drug monitoring”:ab,ti OR “concentration”:ab,ti.
2 #”Drug of choice”/exp OR “Drug of choice”:ab,ti
3 #1 and #2
4 (“Kidney Transplantation”/exp OR “Kidney Transplant”:ab,ti OR “Kidney Transplantation”:ab,ti OR “Renal Transplant”:ab,ti 
OR “Renal Transplantation”:ab,ti AND (reject:ab:ti OR “Graft Rejection”/exp)
5 #3 AND #4
6 #5 AND [humans]/lim AND [english]/lim AND ([adult]/lim OR [aged]/lim)
7 #6 NOT “case report”/de
8 #7 AND [embase]/lim
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Target PK Measure (ng/mL)
Cyclosporine
  Hyperlipidemia 25%-33%{Cheung, 2006, Paired kidney analysis of tacrolimus
and cyclosporine microemulsion-based therapy in Chinese
cadaveric renal transplant recipients; Montagnino, 2002,
Efficacy and safety of tacrolimus compared with cyclosporine
microemulsion in kidney transplantation: twelve-month follow-
up}
2.9–7.2 AUC: 6000–8000* first three 
months, then
4000–6000*{Cheung, 2006, Paired 
kidney
analysis of tacrolimus and 
cyclosporine
microemulsion-based therapy in 
Chinese
cadaveric renal transplant 
recipients}
  Hypertension 58%-75% {Schleibner, 1995, FK 506 versus cyclosporin in the
prevention of renal allograft rejection--European pilot study: six-
week results; Gaber, 2008, Comparison of sirolimus plus
tacrolimus versus sirolimus plus cyclosporine in high-risk renal
allograft recipients: results from an open-label, randomized
trial; Kim, 2004, Randomized trial of tacrolimus versus
cyclosporine in steroid withdrawal in living donor renal
transplant recipients}
Cmin 100–600
  Tremors 27%{Ponticelli, 1996, Randomized study with cyclosporine in




18%-43%{Ponticelli, 1996, Randomized study with
cyclosporine in kidney transplantation: 10-year follow-
up;Cheung, 2006, Paired kidney analysis of tacrolimus and
cyclosporine microemulsion-based therapy in Chinese
cadaveric renal transplant recipients}
2.9–3.2 AUC: 6000–8000* first three 
months, then
4000–6000*{Cheung, 2006, Paired 
kidney
analysis of tacrolimus and 
cyclosporine
microemulsion-based therapy in 
Chinese
cadaveric renal transplant 
recipients}
  Diabetes mellitus 19%{Lee, 2010, Randomized trial of cyclosporine and
tacrolimus therapy with steroid withdrawal in living-donor renal
transplantation: 5-year follow-up}
Cmin 100–350
  Fever 19%{Briggs, 2003, Effects of immediate switch from
cyclosporine microemulsion to tacrolimus at first acute rejection
in renal allograft recipients}
4.2 Cmin 150–300
  Abnormal renal
function
22%-40%{Gaber, 2008, Comparison of sirolimus plus
tacrolimus versus sirolimus plus cyclosporine in high-risk renal
allograft recipients: results from an open-label, randomized
trial; Russ, 2005, Superior outcomes in renal transplantation
after early cyclosporine withdrawal and sirolimus maintenance
therapy, regardless of baseline renal function}
Cmin 50–300
Tacrolimus
  Hypertension 71%{Kuypers, 2004, Clinical efficacy and toxicity profile of
tacrolimus and mycophenolic acid in relation to combined long-
term pharmacokinetics in de novo renal allograft recipients}
Cmin 9.2
  Diabetes mellitus 13%-28%{Langer, 2012, Everolimus plus early tacrolimus
minimization: a phase III, randomized, open-label, multicentre
trial in renal transplantation; Hamdy, 2005, Comparison of
sirolimus with low-dose tacrolimus versus sirolimus-based
calcineurin inhibitor-free regimen in live donor renal
transplantation}
Cmin 1.5–7
  Malignancy 6%{Weir, 2011, Mycophenolate mofetil-based
immunosuppression with sirolimus in renal transplantation: a
Cmin 7.1–5.2


















Target PK Measure (ng/mL)
randomized, controlled Spare-the-Nephron trial}
  Tremor 12%-20%{Laskow, 1996, An open-label, concentration-ranging
trial of FK506 in primary kidney transplantation: a report of the
United States Multicenter FK506 Kidney Transplant Group}
Cmin 5–25
  Infection 52%-67%{Langer, 2012, Everolimus plus early tacrolimus
minimization: a phase III, randomized, open-label, multicentre
trial in renal transplantation; Schleibner, 1995, FK 506 versus
cyclosporin in the prevention of renal allograft rejection–
European pilot study: six-week results}
0.3 Cmin 1.5–7
Sirolimus
  Hyperlipidemia 24%{Vitko, 2006, Tacrolimus combined with two different
dosages of sirolimus in kidney transplantation: results of a
multicenter study}
2
  Rash 14%{MacDonald, 2001, A worldwide, phase III, randomized,
controlled, safety and efficacy study of a sirolimus/cyclosporine
regimen for prevention of acute rejection in recipients of
primary mismatched renal allografts}
5
  Thrombocytopenia 23%{MacDonald, 2001, A worldwide, phase III, randomized,
controlled, safety and efficacy study of a sirolimus/cyclosporine
regimen for prevention of acute rejection in recipients of
primary mismatched renal allografts}
5
  Diabetes mellitus 25%{Lo, 2004, Observations regarding the use of sirolimus and
tacrolimus in high-risk cadaveric renal transplantation}
Cmin
5–10
  Pneumonitis 17%{Lee, 2012, Sirolimus-induced pneumonitis after renal
transplantation: a single-center experience}
Cmin
16.5
AUC: area under the curve at 12 hours; Cmin: minimum concentration
*
ng· hr/mL
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207 Freedom from rejection{Pirsch, 1997, A comparison of
tacrolimus (FK506) and cyclosporine for immunosuppression
after cadaveric renal transplantation. FK506 Kidney Transplant
Study Group}
56% 100–300*
303 Freedom from rejection{Mayer, 1997, Multicenter randomized
trial comparing tacrolimus (FK506) and cyclosporine in the
prevention of renal allograft rejection: a report of the European
Tacrolimus Multicenter Renal Study Group}
54% 100–150*
131 One-year graft survival{Canafax, 1986, Early and late effects of
two immunosuppressive drug protocols on recipients of renal
allografts: results of the Minnesota randomized trial comparing
cyclosporine versus antilymphocyte globulin-azathioprine}
86% 100–200*
142 Three-year graft survival{, 1986, A randomized clinical trial of
cyclosporine in cadaveric renal transplantation. Analysis at




107 Freedom from rejection{Langer, 2012, Everolimus plus early
tacrolimus minimization: a phase III, randomized, open-label,
multicentre trial in renal transplantation}
97% 3.4†
401 Freedom from rejection{Ekberg, 2007, Reduced exposure to
calcineurin inhibitors in renal transplantation}
85% 6.5†
33 Graft survival{Russ, 2003, Reduced and standard target
concentration tacrolimus with sirolimus in renal allograft
recipients}
91% 5.6†
31 Graft survival{Russ, 2003, Reduced and standard target
concentration tacrolimus with sirolimus in renal allograft
recipients}
97% 10†
117 Patient survival {O’Seaghdha, 2009, Higher tacrolimus trough
levels on days 2–5 post-renal transplant are associated with
reduced rates of acute rejection}
97% 11(2–13.5)‡
108 Patient survival{O’Seaghdha, 2009, Higher tacrolimus trough
levels on days 2–5 post-renal transplant are associated with
reduced rates of acute rejection}
98% 24 (20.5–27)‡
401 Patient survival{Ekberg, 2007, Reduced exposure to
calcineurin inhibitors in renal transplantation}
97% 6.5†
Sirolimus
34 Freedom from rejection{Kahan, 1999, Sirolimus reduces the
incidence of acute rejection episodes despite lower
cyclosporine doses in caucasian recipients of mismatched
primary renal allografts: a phase II trial. Rapamune Study
Group; Kahan, 2001, RAD in de novo renal transplantation:
comparison of three doses on the incidence and severity of
acute rejection}
68% 1§
35 Freedom from rejection{Kahan, 2001, RAD in de novo renal
transplantation: comparison of three doses on the incidence
and severity of acute rejection}
85% 4§
64 Patient survival{Dean, 2004, Wound-healing complications
after kidney transplantation: a prospective, randomized
100% 4.2§





















comparison of sirolimus and tacrolimus}
284 Composite: rejection free survival{Kuypers, 2005, Benefit-risk
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